Statement: the primary trial records a total of 7 patients suffering from various infections.
Primary_evidence: Adverse Events 1:   Total: 22/123 (17.89%)   Cardiac Ischemia/Infarction  [1]1/123 (0.81%)   Pain - Chest 2/123 (1.63%)   Dehydration 2/123 (1.63%)   Death  [2]1/123 (0.81%)   Weakness 1/123 (0.81%)   Pain - Liver 1/123 (0.81%)   Infection - Skin  [3]3/123 (2.44%)   Infection - Gastrointestinal  [4]1/123 (0.81%)   Infection - Vein  [5]2/123 (1.63%)   Infection - Pneumonia 1/123 (0.81%)